This bill establishes the Independence Investment Fund inside the Department of the Treasury to deploy capital into companies developing critical and emerging technologies that materially strengthen U.S. national and economic security. Instead of acting as a direct operating agency, the Fund uses an independent managing entity to run investments under Secretary oversight, with governance layers and reporting requirements to Congress.
The statute is designed to nudge private capital toward strategic technology priorities, provide an alternate financing path for companies vulnerable to adversarial foreign investment, and capture market intelligence for the federal government. It also sets out governance mechanics — temporary advisory input, a standing supervisory board, a competitive selection for a managing entity, and annual reporting — and authorizes dedicated appropriations to seed operations and biotechnology investments.
At a Glance
What It Does
Creates a Treasury-based investment vehicle that makes seed-to-mid equity investments in U.S.-headquartered technology companies addressing national and economic security needs; invests through a competitively selected independent managing entity and a supervisory board that approves investments. The Fund may partner with foreign venture funds or invest outside the U.S. except where directed by the bill to exclude ‘‘foreign entities of concern.’'
Who It Affects
Early-stage U.S. companies in critical and emerging technologies (with an explicit biotechnology priority), potential co-investor VCs and foreign partners, the Treasury (which houses the Fund), and the selected managing entity and supervisory board members. Portfolio companies face new reporting and investment-source restrictions spelled out by the statute.
Why It Matters
The measure creates a permanent federal presence in the venture-financing space aimed at both crowding-in private capital and preventing strategic assets from falling under adversarial control. Its combination of direct investment, governance rules, and reporting obligations is intended to reshape financing options for sensitive technology firms and to give policymakers ongoing market visibility.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill authorizes the Secretary of the Treasury to establish the Independence Investment Fund as a distinct entity within the Department. The Fund’s stated mission is to back companies working on technologies listed as ‘‘critical and emerging’’ by the National Science and Technology Council and to use investments to advance measurable national-security or economic-security outcomes.
The Secretary sets overall strategy in consultation with Defense and Commerce, identifying needs and technological priorities the Fund will address.
Operationally, the Fund will not be run directly as a federal operating agency; instead the Secretary must run a competitive process to select an independent managing entity (either nonprofit or for-profit) to manage day‑to‑day investment activity. That managing entity must have prior experience running funds and connecting companies with capital and partners, and it must employ venture-capital practices and provide monthly accounting and quarterly progress reports to the Treasury.
The Secretary and supervisory board retain directional authority over strategic priorities and oversight responsibilities.Investment scope is focused on seed-to-mid-stage equity in companies headquartered in the United States, with the Fund targeting an average investment size in the range of $1 million to $10 million but retaining flexibility to invest any amount. The statute allows, when appropriate, investments in companies based abroad and partnerships with foreign venture funds — but expressly excludes investment from or partnerships with entities designated as foreign entities of concern.
The Fund may also offer non-financial support to portfolio companies (for example, mentorship, regulatory guidance, compute resources, and customer introductions) and the statute contemplates mechanisms for handling intellectual-property considerations and potential resale of equity if a company diverges from the Fund’s objectives.Governance starts with a short-term advisory board that must produce a roadmap and operating guidance within 180 days; that advisory body then sunsets shortly after delivering its report. A standing supervisory board of five members replaces it and functions as the Fund’s investment committee: investments require a quorum of at least four members and approval by at least three.
The law exempts the advisory and supervisory boards from the Federal Advisory Committee Act, streamlines certain contracting authorities for the managing entity, and makes clear that the Fund itself is not to be treated as a federal agency.Accountability and oversight mechanics include an annual report to specified congressional committees every October 1 describing operations, investment performance, progress toward goals and milestones, and how Fund activity complements other federal financing for critical technologies. The statute also authorizes staffing flexibilities for Treasury (up to 25 personnel off the competitive civil‑service grid) and exempts Secretary actions under the Act from the Paperwork Reduction Act and the Administrative Procedure Act to accelerate implementation.
The Five Things You Need to Know
The Fund targets seed-to-mid-stage equity in U.S.-headquartered companies and seeks an average investment size between $1,000,000 and $10,000,000, while retaining flexibility to place larger or smaller investments.
An advisory board must deliver a roadmap and operating guidance within 180 days of enactment and then terminate 90 days after submitting that report to the Secretary and Congress.
A five-member supervisory board serves as the Fund’s investment committee; at least four members must be present for a quorum and at least three affirmative votes are required to approve an investment.
The Secretary must select a managing entity through an open competition and enter into an agreement with that entity no later than 180 days after beginning the competition; the managing entity may be a nonprofit or for-profit organization with demonstrated fund‑management experience.
The bill authorizes $975,500,000 for initial implementation (including a designated $300,000,000 allocation for biotechnology), plus annual administrative funding and a conditional $500,000,000 top-up authority for fiscal years 2035–2040 if the Fund’s biotechnology cash balance falls below $80,000,000.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Key definitions that shape scope and limits
This section defines the statutory terms that determine who and what the Fund can touch: ‘‘critical and emerging technology’’ tracks the NSTC list; ‘‘foreign entity of concern’’ borrows the definition from the Research and Development, Competition, and Innovation Act; ‘‘adversarial investment’’ covers foreign capital or IP acquisition by such entities. By importing those external references, the bill anchors its investment exclusions and partnership rules to existing national-security frameworks rather than creating novel definitions.
Fund charter, objectives, investment scope, and biotech priority
These subsections establish the Fund inside Treasury and enumerate objectives: to make strategic investments that improve national/economic security, to mobilize private capital, to provide an alternative when adversarial investors target firms, and to collect market intelligence. The bill prioritizes biotechnology explicitly. Investment mechanics are seed-to-mid equity for U.S.-headquartered firms, with an average target investment size ($1M–$10M) but without a strict upper limit; limited foreign investments and foreign VC partnerships are allowed provided a counterparty is not a foreign entity of concern.
Advisory board: rapid startup design authority
Congress requires a temporary advisory board to deliver foundational materials — roadmap, bylaws, operating procedures, solicitation terms for the managing entity, investment criteria, and disclosure standards — and to recommend details such as IP handling, board seats, reporting requirements to CFIUS, and prohibitions on portfolio acceptance of foreign‑entity‑of‑concern capital. The advisory board gets a small professional staff and must report within 180 days; it is exempted from FACA and then sunsets shortly after delivering its work.
Supervisory board: standing investment oversight
A permanent five-member supervisory board replaces the advisory board and carries ongoing oversight and investment‑approval authority. Membership must include Treasury and the managing entity, and the initial supervisory board must draw from the advisory board. Voting rules require high participation and multi-member consent, which gives the supervisory board de facto control over individual investment choices and creates a formalized investment-committee structure outside standard federal governance.
Managing entity: competitive selection and delegated execution
The Secretary must hold an open competition to choose an independent managing entity that will run investments using strategic venture-capital practices. Eligibility criteria focus on prior fund-management experience, ability to connect companies to capital and customers, and technology innovation promotion. The managing entity will operate under an agreement that includes monthly financial accounting, quarterly progress reports, conflict-of-interest and transparency requirements, and Secretary direction on national-security and economic priorities.
Staffing flexibilities and annual reporting
Treasury may hire up to 25 personnel outside standard competitive civil-service rules and set pay up to an executive‑branch benchmark. The Fund must provide an annual report to specified congressional committees each October 1 covering operational impacts, investment performance, progress toward advisory-board milestones, and complementarity with other federal financing tools.
Procedural exemptions to speed implementation
Actions taken by the Secretary under the Act are exempt from the Paperwork Reduction Act and from the Administrative Procedure Act’s chapters governing rulemaking and adjudication. Those carve-outs reduce regulatory friction but limit avenues for public review or challenge of implementing decisions.
Appropriations and conditional replenishment
The bill provides a front-loaded authorization to stand up the Fund and prioritizes biotechnology with a designated allocation. It also authorizes recurring administrative funding and creates a conditional, limited $500 million replenishment authority for fiscal years 2035–2040 if the Fund’s biotech cash balance falls below a specified threshold on year‑end accounting.
This bill is one of many.
Codify tracks hundreds of bills on Finance across all five countries.
Explore Finance in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Early-stage U.S. critical-technology companies, especially in biotechnology — they gain a new source of seed-to-mid equity and optional non-financial support (mentoring, regulatory navigation, customer introductions) aimed at keeping strategic capabilities domestic.
- Domestic co-investors and strategic venture funds — the Fund’s participation can de-risk rounds, signal priorities to other investors, and catalyze follow‑on financing when private capital otherwise hesitates.
- Federal national-security and industrial-policy actors (Treasury, DoD, Commerce) — policymakers receive structured market intelligence and a tool for shaping private investment toward prioritized capabilities.
Who Bears the Cost
- U.S. taxpayers — the Fund is backed by congressional appropriations and contingent top-up authorities that commit public dollars to venture-style investments with inherent risk of principal loss.
- Selected managing entity and supervisory board — they assume operational responsibilities, compliance burdens, and reputational risk managing politically sensitive investments under statutory oversight and reporting requirements.
- Portfolio companies seeking global capital — statutory prohibitions and reporting requirements tied to foreign entities of concern may restrict access to some pools of overseas capital and add compliance overhead, potentially complicating future financing rounds.
Key Issues
The Core Tension
The central dilemma is whether a federal-backed investment vehicle can secure strategically important technology through directed capital without distorting private markets, deterring co-investors, or constraining firm exits — in other words, the bill trades faster, government‑guided protection of capabilities for reduced market flexibility and increased public fiscal risk, and there is no clean way to achieve both full market neutrality and robust strategic protection.
The bill walks a narrow line between acting as a strategic investor and preserving private-market dynamics. Delegating investment execution to an independent managing entity is designed to preserve commercial expertise, but the Secretary and supervisory board retain significant directional control and oversight; that hybrid raises accountability questions — who is responsible when investments fail or produce contentious national-security consequences?
The statute’s conflict-of-interest and transparency mandates aim to mitigate those risks, but the managing entity will operate in a quasi-commercial, quasi-public governance environment that invites scrutiny.
The law’s exclusions around ‘‘foreign entities of concern’’ and its encouragement to consider companies blocked by CFIUS inject the Fund directly into geopolitical investment tensions. That posture protects sensitive capabilities but may chill follow-on foreign investment, narrow exit options for founders, and discourage some private co-investors worried about secondary-market limits.
The exemptions from the Paperwork Reduction Act and the Administrative Procedure Act accelerate implementation but reduce procedural guardrails and public notice — speeding action at the cost of external oversight and potential legal review.
Finally, the authorization structure front-loads substantial funds for biotechnology and sets a conditional replenishment many years out; this design creates long-term fiscal exposure and raises questions about how the Fund will balance return-seeking with strategic mandates. The statutory approval thresholds and supervisory-board composition provide strong checks on individual investments, but they also risk slow decision-making and potential groupthink if the board becomes overly cautious or politically influenced.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.